Core Insights - Indaptus Therapeutics has received Clinical Trial Authorization from Health Canada to expand its clinical trial for Decoy20 into Canada, enhancing patient recruitment and clinical research [1][2] - The trial will involve weekly dosing of Decoy20 and aims to evaluate its effectiveness as a broad immune system activator in patients with solid tumors [1][2] - The company plans to submit an amendment to include a combination trial of Decoy20 with Beigene's PD-1 checkpoint inhibitor, tislelizumab [1] Company Overview - Indaptus Therapeutics focuses on innovative cancer and viral infection treatments, leveraging a patented technology that activates both innate and adaptive immune responses [3] - The Decoy platform consists of non-pathogenic Gram-negative bacteria designed to activate immune cells safely through intravenous administration [3] - Pre-clinical studies have shown Decoy product candidates' effectiveness against various cancers and chronic viral infections, demonstrating potential for significant therapeutic advances [3]
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20